modified vaccinia virus ankara vaccine expressing p53
Vaccineexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Oct 1, 2011 (NCT01191684)
Timeline
Indications
Studied for
- Breast Neoplasms · Phase 1
- Carcinoma, Hepatocellular · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1
- Carcinoma, Renal Cell · Phase 1
- Colonic Neoplasms · Phase 1
- Colorectal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Melanoma · Phase 1
- Mutation · Phase 1
- Neoplasms · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 1
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 1
- Stomach Neoplasms · Phase 1
- Urinary Bladder Neoplasms · Phase 1
Mechanism of action
- Cellular tumor antigen p53Immunity, active
TP53 immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- modified vaccinia virus ankara vaccine expressing p53
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03113487 | Phase 2 | Jun 1, 2017 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02432963 | Phase 1 | Nov 17, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT02275039 | Phase 1 | Jan 1, 2015 | City of Hope National Medical Center, National Cancer Institute (NCI) |
| NCT01191684 | Phase 1 | Oct 1, 2011 | City of Hope National Medical Center, National Cancer Institute (NCI) |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| City of Hope National Medical Center | Academic/Hospital | 4 | 4 | 2 | 2011 |
| National Cancer Institute (NCI) | Government | 4 | 0 | 2 | 2011 |
2 organizations
Page 1 / 1